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Abstract
The emergence of resistance to antimicrobial agents is a global public health problem.
Some microorganisms may develop resistance to a single antimicrobial agent (or
related class of agent), while others develop resistance to several antimicrobial agents
or classes. These organisms are often referred to as multidrug-resistant or MDR
strains. Identification of new molecules that show activity against multidrug-resistant
microorganisms and its development on a new antimicrobial drug, would be an
important step in the fight against antimicrobial resistance. This paper presents
experimental data regarding the synthesis of several quinolones. The novel com‐
pounds having quinolone structure were synthesized by Gould-Jacobs method. Their
structure has been determined and confirmed by the following physicochemical
methods: elemental analysis, IR spectral analysis, H-NMR, C-NMR, UV, thin layer
chromatography. The new compounds have been evaluated for „in vitro” activity by
determining minimum inhibitory concentration against a variety of bacteria Some of
new quinolones, which showed a good activity, have been tested against 30 strains of
methicillin resistant Staphylococcus aureus isolated in the Microbiology Laboratory
of INBI Prof. “Dr. Matei Bals” during 2012 The minimum inhibitory concentration
(MIC) of the isolates have been determined by agar plate Mueller Hinton (bioMerieux)
dilution method using the reference strain Staphylococcus aureus ATCC 29213. The
30 strains of isolated have been also tested for susceptibility to ciprofloxacin,
levofloxacin and imipenem by Etest method. Base on the “in vitro” studies, the
quinolone FPQ-30 appears to be an promising compound, all strains isolates were
inhibited at a concentration of 8 μg/ml.
Keywords: Quinolones, fluoroquinolones, antimicrobial agents, Methicillin-resistant
Sthaphilococcus aureus
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1. Introduction
The emergence of resistance to antimicrobial agents is a global public health problem. Some
microorganisms may develop resistance to a single antimicrobial agent (or a related class of
agents), while others develop resistance to several antimicrobial agents or classes. These
organisms are often referred to as multidrug-resistant or MDR strains. Identification of new
molecules that show activity against multidrug-resistant microorganisms and its development
into a new antimicrobial drug would be an important step in the fight against antimicrobial
resistance.
The discovery of fluoroquinolones after 1980 represented a decisive step forward for chemical
anti-infectious therapy. A large number of fluoroquinolones are used today in medical
practices and some of them are deemed by leading pharmacologists to be of vital importance
to anti-infectious therapy.
2. Tendencies and strategies in the field of quinolones
The basic structure of quinolones (Figure 1) [9], is a bicyclic structure that contains a ring type
A 4-pyridinone combined with an aromatic or heteroaromatic ring B. According to the nature
of atoms symbolized by X, Y, Z, they can be defined as four subfamilies: naphthyridine 1-8,
cinnoline, pyrido-2,3-pyrimidines, and quinolone.
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naphthyridines : X=Z=H; Y=N
cinnolin: X=N; Y=Z=H
pyrido-2,3-pyrimidine: X=H; Y=Z=N
quinolones : X=Y=Z= H
Figure 1. Basic structure of quinolones.
The structural modifications of the core of the quinolone influence the antimicrobial activity
2.1. Position 1
Research has been oriented in several directions:
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• Introducing an unsubstituted or substituted alkyl: R 1 = methyl [32], ethyl [32, 28], isopropyl
[28, 48, 1], tert-butyl [48, 14], fluoroethyl [28], hydroxyethyl [38], chloroethyl [38];
• Introduction of a vinyl, allyl [38, 32];
• Introduction of alkylamino groups [65];
• Introduction of a cyclpopropyl [38, 56, 57, 49] or cyclobutyl [49, 1];
• Introducing mono or disubstituted phenyl [38, 7, 46, 49];
• Introduction of a five-membered aromatic heterocycles: pyrrolyl, [34].
Usually, the most active compounds contain the ethyl substituent in position 1. Using a
STERIMOL program, Fujita (1984), based on a set of five parameters that characterize the shape
and size of a substituent and following a quantitative analysis of the relationship between
chemical structure and biological activity on a set of N-1 allyl and alkyl derivatives have
deduced the optimum length of the substituent in position 1 is 0.42 nm [9, 58], which corre‐
sponds to the ethyl substituent. In general, the most active components contain in position 1
an ethyl substituent. These studies have already been confirmed by the results achieved with
quinolones that are used in therapeutic practice: nalidixic acid, oxolinic acid, norfloxacin,
pefloxacin, quinolones that have an ethyl substituent in N-1 position.
In Table 1 is presented the antimicrobial activity for the 1-substituted quinolones against gram
positive and gram negative microorganisms. By comparison, data are entered for norfloxacin
(R1 = ethyl) and ciprofloxacin (R1 = c-C3H5).
Replacing ethyl substituent with:
• Sterically comparable substituents (2-fluoroethyl and vinyl) lead to compounds with
comparable activity on gram negative bacteria, while replacing with substituent steric
hindrance effect more or less pronounced (methyl, 2 hydroxy-ethyl, n-propyl, allyl, benzyl,
cyclopropyl-methyl) leads to decreased activity of “in vitro”.
• Tert-butyl substituent leads to compounds that possess good antimicrobial activity against
Staphylococcus aureus, while against gram negative microorganisms, the activity is compa‐
rable to the reference compound (norfloxacin). Increasing the number of carbon atoms
(number of carbon atoms > 4) results in decreased antimicrobial activity. The replacement
of a hydrogen by fluorine atom leads to the increase of antibacterial activity two to three
times compared to the compound where R1 = tert-butyl, while introducing more fluorine
atoms leads to a decrease in the antimicrobial activity.
In series N-1 cyclopropyl (ciprofloxacin), the substituent from N-1 position has a larger volume
than the ethyl. This is contrary to the concept of the steric volume. High antimicrobial activity
of the ciprofloxacin may be caused by this hyperconjugation or self-association properties
induced by the cyclopropyl. For compounds that present in this position, a cycloalkyl with a
number of carbon atoms of more than 3 (cyclobutyl, cyclopentyl) the antimicrobial activity is
much reduced compared to ciprofloxacin.
The following are relevant for the chemical structure–biological activity relationships:
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• The nature of the substituent introduced in the alkyl moiety at N-1 position of quinolone:
the fluorine atom has benefic influence on the antimicrobial activity;
• The position where the substituents are introduced in the alkyl moiety: substituents in
position 1 of the alkyl moiety have positive influence on antimicrobial activity;
• The number of substituents placed on the alkyl moiety: increasing the number of substitu‐
ents leads to decreased antimicrobial activity;
• Presence of cis-trans stereoisomers: cis derivatives are more active against gram positive
bacteria than the trans derivatives, while the activity is comparable against gram negative
bacteria.
Relevant for the chemical structure–biological activity relationships are to:
• Nature of the substituent introduced in the alkyl moiety at N-1 position of quinolone: the
fluorine atom has benefic influence on the antimicrobial activity;
• The position where the substituents are introduced in the alkyl moiety: substituents in
position 1 of the alkyl moiety have positive influence on antimicrobial activity;
• The number of substituents placed on the alkyl moiety: increasing the number of substitu‐
ents leads to decreased antimicrobial activity;
• Presence of cis-trans stereoisomers: cis derivatives are more active against gram positive
bacteria than the trans derivatives, while the activity is comparable against gram negative
bacteria.
N
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R1
CO2HF
N
HN
Figure 2. Quinolones with an aliphatic substituent in N-1 position.
R1
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
-CH3 6.25 0.39 1.56 (Koga et al. 1980)
-C2H5 (Norfloxacin) 0.39 0.05 0.39 (Koga et al. 1980)
-CH=CH2 3.13 0.10 0.39 (Koga et al. 1980)
n-C3H7 1.56 0.20 3.13 (Koga et al. 1980)
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R1
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
CH2 1.00 0.50 4.00 (Bouzard et al. 1989)
CH2 1.56 0.78 1.56 (Koga et al. 1980)(Bouzard et al. 1989)
1.00 0.50 1.00 (Bouzard et al. 1989)
0.50 0.13 0.50 (Bouzard et al. 1989)
CH
CH3
4.00 2.00 32.00 (Bouzard et al. 1989)
0.25 0.06 0.50 (Remuzon et al. 1991)
0.25 0.50 4.00 (Bouzard et al. 1989)
F 0.13 0.016 0.25 (Remuzon et al. 1991)
F
F 1.00 0.13 1.00 (Remuzon et al. 1991)
-CH2CH2F 1.56 0.10 0,.78 (Koga et al. 1980)
-CH2CH2OH 1.56 0.39 3.13 (Koga et al. 1980)
-NH-CH3 1.95 1.00 1.00
(Koga et al. 1980)
(Wentland et al. 1984)
-CH2-CH=CH2 3.13 0.20 1.56 (Koga et al. 1980)
(Ciprofloxacin)
0.13 0.03 0.013 (Chu&Fernandes 1991)
0.13 0.13 4.00 (Bouzard et al. 1989)
0.25 0.06 0.50 (Bouzard et al. 1989)
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R1
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
(trans)
1.00 0.06 2.00 (Bouzard et al. 1989)
(cis)
0.13 0.13 1.00 (Bouzard et al. 1989)
1.00 1.00 32.00 (Bouzard et al. 1989)
F
(cis)
0.10 ≤0.05 ≤0.05 (Youichi et al. 1994)(Shongo et al. 1993)
F
(trans)
0.78 ≤0.05 0.10 (Youichi et al. 1994)(Shongo et al. 1993)
0.50 0.13 1.00 (Bouzard et al. 1989)
4.00 2.00 32.00 (Bouzard et al. 1989)
0.50 0.25 8.00 (Bouzard et al. 1989)
2.00 1.00 8.00 (Bouzard et al. 1989)
8.00 2.00 63.00 (Bouzard et al. 1989)
Table 1. MIC values (μg/ml) for quinolones with an aliphatic substituent in N-1 position
It is obvious that the volume of the substituent at position N-1 is not the only factor influencing
the antibacterial activity of the quinolones. There are other factors that have a considerable
influence on biological activity such as, for example, the effects of conjugation, conformational
effects. This has been demonstrated by the synthesis of compounds containing aryl substitu‐
ents in N-1 position [32, 7, 8, 46].
In Table 2 are presented data on the antimicrobial activity of 7-piperazinyl and 7- (4-methyl-
piperazinyl)-quinolone derivatives having substituted or unsubstituted aryl substituents in
N-1 position.
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Figure 3. Aryl-quinolones.
Compound R R1 Minimum inhibitory concentration
( μg/ ml)
Reference
S. areus E. coli P. aeruginosa
Norfloxacin 0.39 0.05 0.39 2
1 H H 0.20 0.78 0.78 (Chu et al. 1985)
Sarafloxacin 4-F H 0.20 0.05 0.39 (Chu et al. 1985)
2 H CH3 0.78 0.78 6.20 (Chu et al. 1985)
3 2-F CH3 1.56 0.78 6.20 (Chu et al. 1985)
4 3-F CH3 12.50 6.20 50.00 (Chu et al. 1985)
Difloxacin 4-F CH3 0.20 0.20 1.56 (Chu et al. 1985)
5 4-Br CH3 3.10 6.20 50.00 (Chu et al. 1985)
6 4-Cl CH3 1.56 1.56 12.50 (Chu et al. 1985)
7 4-OH CH3 0.05 0.10 0.39 (Chu et al. 1985)
8 4-OCH3 CH3 1.,50 50.00 200.00 (Chu et al. 1985)
9 4-CH3 CH3 1.56 1.56 12.50 (Chu et al. 1985)
10 3,4-OCH2O- CH3 0.75 0.78 6.20 (Chu et al. 1985)
11 2-F,4v-F CH3 0.10 0.20 1.56 (Chu et al. 1985)
12 2’-CH3 CH3 3.10 1.56 25.00 (Chu et al. 1985)
13 2-CH3,4CH3 CH3 100.00 100.00 100.00 (Chu et al. 1985)
14 4-NO2 CH3 64.00 8.00 128.00 (Radl & Zikan 1989)
15 4-NH2 CH3 2.00 1.00 32.00 (Radl & Zikan 1989)
Table 2. The “in vitro”" antibacterial activity of 1-aryl-quinolones
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For 7-piperazinyl quinolones, the introduction of an unsubstituted aryl affords a compound
(compound 1 – Table 2) with good antimicrobial activity “in vitro” against S. aureus being more
active than the reference compound, norfloxacin.
The presence of a substituent on the aryl nucleus leads to improved antimicrobial activity, e.g.
a fluorine atom (sarafloxacina) in the 4-position of the phenyl ring.
In the series 7-(4-methyl-piperazinyl)-1-aryl-quinolones the best results are obtained when in
position 4 is located a fluorine atom (for example, difloxacin) or -OH (compound 7). Good
results are also obtained in the case of two substituents present (positions 2 and 4) on the aryl
nucleus (R = F) (compound 11).
2.2. Position 2
Some changes were explored for this position [9]. Replacing the carbon atom of oxolinic acid
with a nitrogen atom (which led to cinoxacin) has resulted in improved pharmacokinetic
properties, but has led to decreased antimicrobial activity “in vitro”. Significant reductions in
bacterial activity were also observed in the case of 2-aza-4-quinolones derivatives from
norfloxacin and pefloxacin. The introduction of substituents on the carbon atom in position 2,
for example, hydroxy, methyl, methylthio, etc., leads to the inactivation of the quinolone
compounds.
2.3. Position 3
In the quinolone molecule, combination between carboxyl group from 3 position and ketone
group in 4 position, is considered necessary for binding to DNA gyrasa, while the presence of
carboxyl group in 3 position is essential for antimicrobial activity. Modification of carboxyl
groups, generally leads to obtaining biologically inactive compounds (Figure 4) [62]. The
exceptions are groups that can be converted “in vitro” to the carboxyl function.
N
O
O
S
XF
N
NCH3
Figure 4. X = H, 4b: X = SO3H
The researches regarding changes of the substituent in the 3 position of quinolone, followed
to obtain:
• Compounds presenting free carboxyl group;
• Bioreversible compounds (prodrugs) ester (Figures 5, 6), [59, 51], which easily hydrolyzed
in the body releasing the carboxyl group;
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Figure 5. Methyl-2-oxo-1,3-dioxol-4-yl) ethyl ester
N
O
COOCH2OCOC(CH3)3F
N
HN
S
H3C
Figure 6. Pivaloiloxymethyl ester
N
O
CHOF
N
HN R1
Figure 7. R1 = ethyl, cyclopropyl, R = H, methyl
• Bioreversible derivatives (prodrugs) - 3-formyl-quinolone (Figure 7) [31];
• Quinoline-3-carboxamide: (Wetland et al. 1993), (Sajay et al. 2000).
N
O
CONH2
R1N
Figure 8. R1 = alkyl, mono or disubstituted phenyl
Both types of structures (Figures 8 and 9) have been hydrolyzed in the body; carboxyl group
has been generated; and through this the biological activity was explained, with the observa‐
tion that the time to reach that MICs is greater.
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2.4. Position 4
The quinolone structure requires the presence of the ketone group in position 4. Replacing this
ketone group, the 4-thiooxo or 4-sulfonyl groups led to obtaining inactive compounds [9].
2.5. Position 5
In position 5 of the quinolones various groups were introduced, such as nitro (Domagala et al.
1988) unsubstituted or substituted amino [27, 16, 36] [17], alkyl [23, 25], halogen [35, 36],
mercapto [35, 36], hydroxy [36, 17], alkoxy or tioalcooxi [35, 36]
N
O
CO2HF
N
R5
R8NR
Figure 10. Substituted quinolones.
R R5 R8 Minimum inhibitory concentration
( μg/ml)
Reference
S. aureus E. coli P. aeruginosa
H H H 0.2 0.013 0.4 (Domagala et al.1991)(*)
H NH2 H 0.025 0.013 0.8 (Domagala et al.1991)(*)
H NH2 F
0.013
0.013
0.050
0.013
0.013
0.0063
0.025
0.025
0.1
(Domagala et al.1991)(*)
(Domagala et al.1988)(*)
(Myamoto et al. 1990) 74(**)
H CH3NH F 0.2 0.1 1.6 (Domagala et al.1988)( *)
H AcNH F >25 >25 >25 (Domagala et al.1988)( *)
H NH2 Cl 0.025 0.025 0.8 (Domagala et al.1991)(*)
H HO H 0.2 0.025 0.4 (Domagala et al.1991)(*)
N
O
CX
Y
Z
O
NH
R
H
Figure 9. X = H,Cl,F,NO2, Y = H,Cl,NO2 Z = H,CH3,F, R = cyclopropyl, n-octyl, (N, N-diethylamino-1-methyl) butyl
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R R5 R8 Minimum inhibitory concentration
( μg/ml)
Reference
S. aureus E. coli P. aeruginosa
H HO F 0.20.2
0.05
0.025
0.8
0.39 (Myamoto et al. 1990) (**)
H CH3 H 0.025 0.013 0.2 (Hagen et al. 1991) (*)
H CH3 F 0.025 0.025 0.2 (Hagen et al. 1991) (*)
H CH3 Cl 0.025 0.025 0.2 (Hagen et al. 1991) (*)
H C2H5 H 6.30 0.4 12.5 (Hagen et al. 1991) (*)
H F F 0.2 0.0125 0.39 (Myamoto et al. 1990) (**)
H Cl F 0.1 0.0125 0.39 (Myamoto et al. 1990) (**)
CH3 H F 0.2 0.025 0.39 (Myamoto et al. 1990) (**)
CH3 F F 0.39 0.05 0.78 (Myamoto et al. 1990) (**)
CH3 Cl F 0.2 0.025 0.78 (Myamoto et al. 1990) (**)
CH3 Br F 0.39 0.05 0.78 (Myamoto et al. 1990) (**)
CH3 HO F 0.2 0.05 0.78 (Myamoto et al. 1990) (**)
CH3 CH3O F 25 0.2 12.5 (Myamoto et al. 1990) (**)
CH3 PhCH2O F 6.25 1.56 6.25 (Myamoto et al. 1990) (**)
CH3 HS F 3.13 0.39 12.5 (Myamoto et al. 1990) (**)
CH3 CH3S F 3.13 0.2 12.5 (Myamoto et al. 1990) (**)
CH3 4-CH3OPhCH2S F 100 12.5 >100 (Myamoto et al. 1990) (**)
CH3 NH2 F
0.1
0.013
0,0125
0.025
0.2
0.1
(Domagala et al.1988)( *)
(Myamoto et al. 1990) (**)
CH3 CH3NH F 0.78 0.1 1.56 (Myamoto et al. 1990) (**)
CH3 (CH3)2N F
25
>25
3,.3
>25
50
>25
(Domagala et al.1988)
(Myamoto et al. 1990) (**)
CH3 PhCH2NH F 0.78 0.78 3.13 (Myamoto et al. 1990) (**)
CH3 HOCH2CH2NH F 0.39 0.5 0.78 (Myamoto et al. 1990) (**)
CH3 (CH3)2NCH2CH2NH F 6.25 0.05 0.78 (Myamoto et al. 1990) (**)
CH3 pyrrolyl F 3.13 0.39 12.5 (Myamoto et al. 1990) (**)
Ciprofloxacina ; * S. aureus UC 76 ; * E. coli Vogel; * P. aeruginosa.UI-18; **S. aureus 209P JC-1 ; **E. coli NIIHJ JC-2; **P.
aeriginosa 12
Table 3. The “in vitro” antibacterial activity of 5-substituted quinolones
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In the series of 1-cyclopropyl-7-piperazinyl quinolones, the influence of the substituent in position
5 on the antimicrobial activity is manifested as follows:
• The introduction of unsubstituted amino group when R8 = H leads to increased antibacterial
activity against gram positive only, while when R8 = F or Cl leads to the increase of anti‐
bacterial activity on gram positive and gram negative microorganisms.
• The introduction of substituted amino group leads to the lowering of antimicrobial activity
on the entire microbial spectrum.
• The introduction of the hydroxy group (R8 = H, F), does not produce any change in the
antibacterial activity.
• The introduction of the methyl group (R8 = H, F, Cl) causes increased activity on the entire
microbial spectrum.
• The introduction of an alkyl radical having a carbon number greater than 2 leads to
decreased antimicrobial activity.
• The introduction of a halogen atom:
• For R5 = F (R8 = F) – the antimicrobial activity remains unchanged on the entire microbacterial
spectrum.
• For R5 = F (R8 = F) – antibacterial activity is improved against gram positive bacteria).
In the series of 1-cyclopropyl-7-(4-methyl-piperazinyl)-quinolones, the influence of the substituent
in position 5 on the antimicrobial activity is manifested as follows:
• The introduction of an unsubstituted amino group (R8 = F) leads to increased antibacterial
activity against gram positive and gram negative microorganisms; the alkylation of the
amino group leads to the lowering of antimicrobial activity on the entire microbial spectrum,
the decrease being dependent on the size of the alkyl group (especially dialkylating lead to
a loss of antibacterial activity).
• The introduction of a halogen atom (fluorine or bromine) (R8 = F) leads to the slight decrease
of activity compared to the unsubstituted compound; the introduction of a chlorine atom
decreases antibacterial activity only against Pseudomonas aeruginosa.
• The introduction of a hydroxy group does not modify the biological activity. The introduc‐
tion of a methoxy or benzyloxy group leads to decreasing of the antimicrobial activity
against all tested microorganisms.
• The introduction of a mercapto group leads to a considerable decrease of the antimicrobial
activity on the entire microbial spectrum. The same decrease is found in the case of meth‐
ylthio group.
• The presence of a bulky substituent leads to the loss of biological activity against all
microorganisms tested.
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2.5.1. In conclusion
In the case of 1-cyclopropyl-7-piperazinyl-quinolones, antibacterial activity increases accord‐
ing to the nature of the substituent in position 5, in the following order:
For R8 = H : RO < HO < NH2 < CH3;
For R8 = F : HO ≤ F ≤ Cl < CH3 < F
In the case of 1-cyclopropyl-7-(4-methyl-piperazinyl)-8-fluoro-quinolones, antibacterial
activity increases according to the nature of the substituent in position 5, in the following order:
R2N < RH < SH < RO < RNH < Br F ≤ HO ≤ Cl < NH2
2.6. Position 6
The nature of the substituent from this position influences the inhibition activity of DNA
gyrase and cell penetration.
In this position the following substituents have been introduced: H, F, Cl, Br, CH3, NO2, NH2
[32, 5, 7, 34, 29, 4, 5].
The introduction of a fluorine atom in this position has lead to a spectacular increase of
the  antibacterial  activity,  compared  to  unsubstituted  compound  (R6  =  H)  (activity  of
norfloxacin against E. coli R6 = F, is 16 times higher than the nonfluorinated compound in
position 6) (Table 6).
Regarding the importance of the presence of fluorine atom in position 6 of the quinolone, other
authors (Ledoussant et al. 1992) have reported that this is essential for the activity of the
quinolone compounds.
R6 Minimum inhibitory concentration
( μg / ml)
Reference
S. aureus E. coli P. aeruginosa
H 12.50 0.78 3.13 (Koga et al. 1980)
F: Norfloxacina 0.39 0.05 0.39 (Koga et al. 1980)
Cl 1.56 0.20 3.13 (Koga et al. 1980)
Br 3.13 0.39 1.50 (Koga et al. 1980)
CH3 3.13 0.39 6.25 (Koga et al. 1980)
SCH3 25.00 0.78 12.50 (Koga et al. 1980)
COCH3 100.00 100.00 100.00 (Koga et al. 1980)
CN 12.50 0.39 6.25 (Koga et al. 1980)
NO2 25.00 0.78 12.50 (Koga et al. 1980)
Table 4. The “in vitro” antibacterial activity of 6 substituted quinolones
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NO
CO2H
C2H5
N
R6
HN
Figure 11. Substituted quinolones.
There have been synthesized compounds containing an amino group at position 6 [3-5]. A
direct comparison between 6-amino-quinolones and 6-fluoro-quinolones shows a decrease of
antimicrobial activity of 6-amino-quinolones of about 28–300 times (Table 7). The antimicrobial
activity of 6-amino-quinolones can be improved by optimizing the chemical structure through
the introduction of various substituents in other positions of the quinolones core.
R1 R5 R7 R8 Minimum inhibitory concentration
(μg/ml)
Reference
S. aureus E. coli P. aeruginosa
1 a -c-C3H5 H Piperazinyl H 0.25 64.00 2.00
(Cecheti et al.
1995)
2 a -c-C3H5ciprofloxacin H Piperazinyl H 0.12 0.03 0.06
(Cecheti et al.
1995)
1 b -c-C3H5 H 4-Methyl-piperazinil H 0.25 2.00 4.00
(Cecheti et al.
1995)
1 c -c-C3H5 H Tiomorpholinyl F 0.12 0.25 4.00
(Cecheti et al.
1995)
1 d -c-C3H5 NH2 4-Methyl-piperazinyl H 128 16 128
(Cecheti et al.
1995)
1 e -c-C3H5 NH2 4-Methyl-piperazinyl F 2 0.03 4
(Cecheti et al.
1995)
1 f -c-C3H5 H 4-Methyl-piperazinyl F 4 1 2
(Cecheti et al.
1995)
1 g t-Bu H 4-Methyl-piperazinyl H 2 0.06 2 (Cecheti et al.1995)
1 h 4-FC6H4 H 4-Methyl-piperazinyl H 8 0.12 8
(Cecheti et al.
1995)
Table 5. The “in vitro” antibacterial activity of 6-amino-quinolones.
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CO2H
R1R8
R5
F
R7
Figure 12. Amino-quinolones and 6-fluoro-quinolones.
2.7. Position 7
Modifications in position 7 have been the most intensively studied; studies have shown that
the nature of the substituent from this position has a great influence on the biological potential,
antibacterial spectrum, solubility, and on the pharmacokinetics (bioavailability). Research has
been focused in the following areas: introduction of piperazinyl, mono or disubstituted
piperazinyl, morpholinyl or thiomorpholinyl, pyrrolidinyl, piperidinyl, azetidinyl, bicyclic
heterocycles, 4-pyridinyl.
Influence of the nature of the substituent in position 7 on the antibacterial activity is closely
related to the nature of the substituents from the other positions of the quinolones core,
especially the nature of the substituents at the nitrogen in position 1.
For 1-ethyl-6-fluoro-7-substituted-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (Table 6), it was
observed that the best influence on antimicrobial activity is the introduction of a piperazinyl
group (norfloxacin). Introducing the piperazinyl group in position 7 of the quinolone ring leads
to a product with a higher antibacterial potential. The antibacterial spectrum of norfloxacin
includes both gram positive and gram negative bacteria, in particular more strains of P.
aeruginosa.
N
O
C2H5
CO2HF
R7
Figure 13. Ethyl-7-substituted-quinolones.
R7 Minimum inhibitory concentration
(μg/ml)
Reference
S. aureus E. coli P. aeruginosa
Chlor 12.50 1.56 100.00 (Koga et al.1980)
Methyl 6.25 0.39 5000 (Koga et al.1980)
Amino 100.00 3.13 100.00 (Koga et al.1980)
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R7 Minimum inhibitory concentration
(μg/ml)
Reference
S. aureus E. coli P. aeruginosa
Methylamino 12.50 3.10 100.00 (Koga et al.1980)
Dimethylamino 0.78 0.39 50.00 (Koga et al.1980)
S(CH2)2NH2 25.00 0.80 3.10 (Chu & Fernandes 1991)
Piperazinyl (norfloxacin) 039 0.05 0.39 (Koga et al.1980)
4-Methyl-piperazinyl 0.39 0.10 1.56 (Koga et al.1980)
4-Allyl-piperazinyl 0.39 0.39 6.25 (Koga et al.1980)
4-Benzyl-piperazinyl 0.39 0.79 50.00 (Koga et al.1980)
4- (4-Nitro-benzyl) -piperazinyl 1.56 6.25 100.00 (Koga et al.1980)
4- (4-Amino-benzyl) -piperazinyl 0.39 0.39 12.50 (Koga et al.1980)
4-Benzoyl-piperazinyl 1.56 3.13 25.00 (Koga et al.1980)
4- (2-Hydroxyethyl) piperazinyl 0.78 0.10 6.25 (Koga et al.1980)
3- (Hydroxymethyl) piperazinyl 8.00 2.00 64.00 (Ziegler et al. 1990)
3-Fluoromethyl-piperazinyl 0.12 0.12 32.00 (Ziegler et al. 1990)
3-Difluoromethyl-piperazinyl 0.12 0.50 32.00 (Ziegler et al. 1990)
Morpholinyl 0.78 0.20 12.50 (Koga et al.1980)
Thiomorpholinyl 0.06 1.60 12.50 (Chu & Fernandes 1991)
1-Piperidinyl 0.78 1.56 50.00 (Koga et al.1980)
4-Hydroxy-piperidinyl 0.39 0.39 6.25 (Koga et al.1980)
4-Dimethylamino-piperidinyl 0.39 0.10 3.13 (Koga et al.1980)
Pyrrolidinyl 0.20 0.39 12.50 (Koga et al.1980)
Pyrrolidyl 0.40 1.60 12.50 (Chu & Fernandes 1991)
Thiazolidinyl 0.20 0.20 3.10 (Chu & Fernandes 1991)
1-Imidazolyl 0.25 1.56 12.50 (Toshio et al. 1987)
1-Pyrazolyl 6.25 12.50 25.00 (Toshio et al. 1987)
1-Pyrrolyl 0.39 3.13 12.50 (Toshio et al. 1987)
1,2,4-Triazol-4-yl 25.00 25.00 25.00 (Toshio et al. 1987)
3-Amino-3-methyl-1-azetidinyl 0.50 0.50 2.00 (Toshio et al. 1987)
Table 6. The “in vitro” antibacterial activity of 1-ethyl-7-substituted-quinolones.
For 1-cycloprpyl-6-fluoro-7-substituted-4-oxo-1,4-dihydro-quinoline-3-carboxylic acid (Table 7) it
was observed:
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• Introducing a piperazinyl moiety (ciprofloxacin) yields a compound with a higher antibac‐
terial potential; a similar antibacterial activity is obtained in the case where R7 is 3-methyl-
piperazinyl (Compound 1B);
• Introducing the pyrrolidinyl moiety (4A-4E compounds) gives a good bacterial activity on
the entire bacterial spectrum, especially in the case of compound 4A where R7 = 3-amino-
pyrrolidinyl;
• Introducing an azetidinyl moiety (Compound 8A) leads to an approximately twofold
increase in activity against gram positive bacteria compared to ciprofloxacin; activity against
gram negative microorganisms is 4-15 times lower. Introduction of a substituent on the
azetidinyl moiety offers compounds with increased activity in the following order: 8I(ami‐
nomethyl) ≈ 8J(thia) < 8D(ethylamino) < 8E(dimethylamino) < 8C(methylamino) < 8B(ami‐
no). For the 7-(3,3-di-azetidinyl)-quinolone, antibacterial activity increases in the following
order: 8K (aminomethyl) ≈ 8L (ethylaminomethyl) < 8H (dimethylamino) < 8C (methylami‐
no) < 8F (amino). In conclusion, the activity “in vitro” of the compounds 8B and 8F increases
on the entire bacterial spectrum and can be compared with that of ciprofloxacin. For
compounds where R7 are 3-amino-2-methyl-azetidinyl (compounds 9A–9H), the effect
given by the stereochemistry of the substituents in the azetidinyl moiety has been studied.
The activity “in vitro” of the compound trans-7-(3-amino-2-methyl-azetidinyl) quinolone
9A can be compared favorably with the activity of 3-monosubstituted-azetidinyl, 3,3-
disubstituted-azetidinyl and ciprofloxacin.
N
O
CO2HF
R7
Figure 14. Cyclopropyl-7-substituted-quinolones.
Comp. R7
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
1A Piperazinyl (ciprofloxacin) 0.13 0.03 0.13 (Bouzard et al.1989)
1B 3-Methyl-piperazinyl 0.12 0.015 0.25 (Ziegler et al.
1990)1C 3-Fluoromethyl-piperazinyl 0.12 0.06 2.00
2A Morpholinyl 0.05 0.20 1.56 (Kazico et al.
1993)2B 3-Aminomethyl-morpholinyl 0.20 0.20 1.56
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Comp. R7
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
3A Homopiperazinyl 0.25 0.03 1.00
(Ziegler et al.
1990)3B 3-Hydroxy-homopiperazinyl 4.00 0.25 2.00
3C 3-Fluoro-homopiperazinyl 0.25 0.03 2.00
4A 3-Amino-pyrrolidinyl 0.025 0.025 0.1-0.2
(Domagala et
al.1993)
4B 3-Aminomethyl-pyrrolidinyl 0.006 0.05 0.80
4C 3-Methylamino-pyrrolidinyl 0.025 0.10 0.80
4D 3-Thia-pyrrolidinyl 0.013 0.20 1.6
4E 3-Aminomethyl-3-methyl-pyrrolidinyl 0013 0.20 0.80
5 3-Hydroxy-pyrrolidinyl <0.015 <0.015 0.125 (Petersen &Grohe 1992)
6 3-Oxo-pyrrolidinyl 1.56 6.20 100.00 (Cooper et al.1992)
7A 3-Amino-4-trans-cyclopropyl-pyrrolidinyl <0.025 0.05 0.80
(Bush et al.
1993)7B 3-Amino-4-trans-(trans-2-CO2Et)-cyclopropyl- pyrrolidinyl 0.20 0.20 3.10
8A Azetidinyl 0.06 0.12 2.00
(Frigola et al.
1993)
8B 3-Amino-azetidinyl 0.25 0.03 0.25
8C 3-Methylamino-azetidinyl 0.25 0.03 0.50
8D 3-Ethylamino-azetidinyl 0.25 0.06 2.00
8E 3-Dimethylamino-azetidinyl 0.12 0.06 2.00
8F 3-Methyl-3-amino-azetidinyl 0.12 0.06 0.50
8G 3-Methylamino-3-methyl-azetidinyl 0.25 0.06 2.00
8H 3-Dimethylamino-3-methyl-azetidinyl 0.25 0.25 4.00
8I 3-Aminoethyl-azetidinyl 0.50 0.12 1.00
8J 3-Thia-azetidinyl 0.50 0.25 4.00
8K 3-Aminomethyl-3-methyl-azetidinyl 0.25 0.12 1.00
8L 3-Thia-3-methyl-azetidinyl 0.25 0.12 4.00
9 N
R19
R21
R20
R18
(Frigola et al.
1994)
R18 R19 R20 R21
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Comp. R7
Minimum inhibitory concentration
(μg/ml) Reference
S. aureus E. coli P. aeruginosa
9A CH3 H H NH2 0,12. 0.03 0.25
9B CH3 H NH2 H 0.12 0.06 0.50
9C C2H5 H NH2 H 0.25 0.12 2.00
9D H CH3 NH2 CH3 0.25 0.06 2.00
9E H CH3 NHCH3 H 0.12 0.06 0.50
9F H CH3 N(CH3)2 H 0.25 0.50 4.00
9G H CH3 CH2NH2 H 0.25 0.12 2.00
9H H CH3 CH2NHC2H5 H 0.25 0.12 4.00
Table 7. The “in vitro” antibacterial activity of 1-cyclopropyl-7-substituted-quinolones.
For 1-(p-fluorophenyl)-7-substituted-quinolones (Table 8), it is observed that the introduction of
substituents: 3-methyl-piperazinyl (4), 4-amino-piperazinyl (8), 3 amino-pyrrolidinyl) (17),
and 3-methyl-2-amino-pyrrolidinyl (20) has the effect of extending of the antibacterial
spectrum on both gram positive and gram negative bacteria, while introducing morpholinyl
groups (10), thiomorpholinyl (11), 4-hydroxy-piperidinyl (13), pyrrolidinyl (15), 3-hydroxy-
pyrrolidinyl (compound 16) leads to the increase of antibacterial activity against gram positive
bacteria, comparable with the antibacterial activity of the sarafloxacin and difloxacin. It should
be noted that the introduction of the methyl group in position 5 of 3-amino-pyrrolidinyl
substituent (compound 17) leads to obtaining a compound (20) with a high solubility in water
and with excellent efficacy in oral administration.
N
O
CO2H
R7
F
F
Figure 15. p-Fluorophenyl)-7-substituted-quinolones.
Structural changes were focused on replacing the nitrogen atom of the heterocyclic substituent
with a sp2 or sp3 hybridized carbon atom. All new compounds have a high activity both “in
vitro” and “in vivo”. The potential of these compounds is relatively dependent on the size of
the ring and the hybridization of the carbon atom through which it connects with the quino‐
lone. 1-Piperazino moiety can be substituted with 4-piperidinyl (compound 1, Table 9) with
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4-(1,2,3,6-tetrahydropyridinyl) (compound 2), while the 3-amino-pyrrolidinyl moiety can be
substituted with 3-amino-cyclopentanyl (compound 3). For the compounds 1 and 2, the nature
of isosteric atom that replaces the nitrogen atom in position 1 of the piperazinyl moiety
influences the antimicrobial activity “in vitro” as follows: while this sp2 hybridized atom
(through which connects the quinolone nucleus) leads to compounds (2) with activity com‐
parable to ciprofloxacin, the presence of carbon sp3 leads to decreased activity “in vitro” of
about 4–12 times. Replacement of the 3-amino-1-pyrrolidinyl (compound B) with 3-amino-1-
R7 Minimum inhibitory concentration
(μg/ml)
Reference
S. aureus E. coli P. aeruginosa
1 Piperazinyl (sarafloxacina) 0.20 0.05 0.39 (Chu et al. 1985)
2 4-Methyl-piperazinyl (difloxacin) 0.20 0.20 1.56 (Chu et al. 1985)
3 4-Butyl-piperazinyl 0.78 1.56 12.50 (Chu et al. 1985)
4 3-Methyl-piperazinyl 0.20 <0.05 0.78 (Chu & Fernandes 1991)
5 3,5-Dimethyl-piperazinyl 0.39 <0.05 1.56 (Chu & Fernandes 1991)
6 3-Fluoromethyl-piperazinyl 0.25 0.25 2.00 (Domagala et al. 1988)
7 3-Oxo-piperazinyl 0.20 0.20 1.56 (Chu et al. 1985)
8 4-Amino-piperazinyl 0.39 0.20 0.78 (Chu & Fernandes 1991)
9 Homopiperazinyl 0.79 0.20 1.56 (Chu et al. 1985)
10 Morpholinyl 0.10 0.39 3.10 (Chu et al. 1985)
11 Thiomorpholinyl 0.05 0.78 3.10 (Chu et al. 1985)
12 Piperidinyl 0.20 1.56 6.20 (Chu et al. 1985)
13 4-Hydroxy-piperidinyl 0.10 0.39 6.20 (Chu et al. 1985)
14 4-Dimethylamino-piperidinyl 0.39 0.73 3.10 (Chu et al. 1985)
15 Pyrrolidinyl 0.10 0.78 1.56 (Chu et al. 1985)
16 3-Hydroxy-pyrrolidinyl 0.10 0.20 3.10 (Chu et al. 1985)
17 3-Amino-pyrrolidinyl 0.10 <0.05 0.78 (Chu & Fernandes 1991)
18 3-Methylamino-pyrrolidinyl 0.20 <0.05 1.56 (Chu & Fernandes 1991)
19 3-Dimethylamino-pyrrolidinyl 0.78 <0.05 6.25 (Chu & Fernandes 1991)
20 3-Methyl-3-amino-pyrrolidinyl 0.05 0.02 0.78 (Rosen et al. 1988)
21 Trans (3-amino-2-methyl) -azetidinyl 0.25 0.12 1.00 (Domagala et al. 1988)
22 3-Amino-3-methyl-azetidinyl 0.12 0.12 2.00 (Domagala et al. 1988)
6-Fluoro-1,4-dihydro-4-oxo-quinoline-3-carboxylic acids substituted in position 7 with bioisosteric non-basic groups.
Table 8. The ”in vitro” antibacterial activity of 1-(p-fluorophenyl)-7-substituted-quinolones.
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cyclopentanyl (compound 3) results in a decrease in antimicrobial activity. In general, the
piperazinyl moiety in position 7 has a favorable influence at the “in vitro” activity, but 7-
substituted piperazinyl quinolones do not have a good availability.
N
O
CO2HF
R7
Figure 16. Cyclopropyl-quinolones substituted in position 7 with bioisosteric non-basic groups.
Compound R7 Minimum inhibitory concentration
( μg / ml)
Reference
S. aureus E. coli P. aeruginosa
A HN N 0.13 0.03 0.13 (Bouzard et al. 1989)
1 HN 0.80 0.20 1.60 (Laborde et al. 1993)
2 HN 0.10 0.025 0.80 (Laborde et al. 1993)
B N
H2N 0.025 0.025 0.20 (Laborde et al. 1993)
3 N
H2N
0.10 0.10 0.80 (Laborde et al. 1993)
Table 9. The “in vitro” antibacterial activity of 1-cyclopropyl-quinolones substituted in position 7 with bioisosteric
non-basic groups.
2.8. Position 8
The most famous modifications of the 8 position of the quinolone are X = CH or N (naphthyr‐
idines). However, compact and lipophilic groups: X = CR8, where R8 = fluorine [16, 17, 25, 54],
trifluoromethyl [52] and methoxy [22, 55] have gained ground due to the positive influence
they have on the antibacterial activity.
Quinolone Compounds with Activity Against Multidrug-Resistant Gram-Positive Microorganisms
http://dx.doi.org/10.5772/60948
65
NO
R1
CO2H
R5
R5
R5
R8
R8 = F, Cl, OCH3 > H, CF3 > methyl, vinyl, propargyl
Figure 17. Influence of the nature of the substituent at 8 position on the antimicrobial activity.
In general, the introduction of a fluorine atom in 8 position leads to increased antibacterial
activity against gram negative microorganisms, while introducing the methoxy group increase
the activity only against the gram positive bacteria.
N
O
CO2HF
N
R8
H2N
Figure 18. Cyclopropyl-8-substituted quinolones.
R8 Minimum inhibitory concentration
(μG / ML) geometric mean
Gram (-)organisms Gram (+)organisms
H 0.09 0.14
F 0.04 0.03
OMe 0.07 0.03
Cl 0.03 0.04
NO2 0.46 0.92
NH2 0.53 0.06
CF3 0.20 0.20
SMe 0.20 0.06
Table 10. The “in vitro” antibacterial activity 8 substituted quinolones.
The compounds containing a chlorine atom in 8 position [30, 25, 17] are very active, as well as
analogs containing fluorine or methoxy moiety [22, 55]. The introduction of bulky substituents,
e.g., ethyl, reduces the antibacterial activity against gram negative (if a comparison with 8-
methoxy-quinolones is made). Quinolones having a halogen atom, fluorine or chlorine in 8
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position, show the phototoxicity; the introduction of trifluoromethyl group [52] leads to
reduced cytotoxicity. Alkylation of carbon in position 8 is tolerated, especially if the substituent
is lipophilic and has a small volume. Thus the introduction of the methyl group [4, 5] leads to
compounds with modest antibacterial activity. Instead, amino, nitro, hydroxy substituents
lead to loss of antibacterial activity (Dax 1997).
3. New compounds: synthesis, structure and antimicrobial activity
3.1. Structure of the new compounds
A series of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acids was synthesized. (Figure 19) (Table
11). Their structure has been determined and confirmed by the following physicochemical
methods: elemental analysis, IR spectral analysis, H-NMR, C-NMR, UV, thin layer chroma‐
tography.
N
O
CO2H
R1
R7
R6
R8
Figure 19. Structure of 4-oxo-1,4-dihydro-quinoline-3-carboxylic acids.
Quinolones R1 R6 R7 R8 m.p. (°C) Reference
FPQ 24
C18H21FN2O3
Ethyl F 3-Methyl-piperidin-1-yl H 189.4 Pintilie et al.(2009b)
FPQ 30
C18H20ClFN2O3
Ethyl F 3-Methyl-piperidin-1-yl Cl 163-165.3 Pintilie et al.(2014a)
FPQ 32
C17H19FN2O3
Ethyl F Piperidin-1-yl H 202.4-204.4
Pintilie & Nita
(2011a)
FPQ 33
C17H18ClFN2O3
Ethyl F Piperidin-1-yl Cl 186-191.2 Pintilie & Nita(2011a)
Q 83
C18H21FN2O3
Ethyl F 4-Methyl-piperidin-1-yl H 235-237 Pintilie et al.(2003b)
Q 85
C18H20 ClFN2O3
Ethyl F 4-Methyl-piperidin-1-yl Cl 201-202.5 Pintilie et al.(2003b)
FPQ 35
C16H17FN2O3
Ethyl F Pyrrolidin-1-yl H 336.6-337.9
Pintilie & Nita
(2011a)
FPQ 36 Ethyl F Pyrrolidin-1-yl Cl 214.5-217.8
Pintilie & Nita
(2011a)
Quinolone Compounds with Activity Against Multidrug-Resistant Gram-Positive Microorganisms
http://dx.doi.org/10.5772/60948
67
Quinolones R1 R6 R7 R8 m.p. (°C) Reference
C16H16ClFN2O3
FPQ 25
C16H17FN2O4
Ethyl F Morpholin-1-yl H 257.4-258.7
Pintilie et al.
(2009b)
FPQ 28
C16H16ClFN2O4
Ethyl F Morpholin-1-yl Cl 244.6-244 Pintilie et al.(2014a)
NF
C16H18FN3O3
Ethyl F Piperazin-1-yl H 218-220 Pintilie et al.(2014b)
AcNF
C18H20FN3O4
Ethyl F 4-Acetyl-piperazin-1-yl H 297.8-299.9
Pintilie et al.
(2014b)
AcFPQ 50
C18H19ClFN3O4
Ethyl F 4-Acetyl-piperazin-1-yl Cl 255.7-258.2
Pintilie et al.
(2014b)
FPQ 50
C16H17ClFN3O3
Ethyl F Piprazin-1-yl Cl 227-230 Pintilie et al.(2014b)
PF
C17H20FN3O3
Ethyl F 4-Methyl-piperazin-1-yl H
269.2-272.
8
Pintilie et al.
(2014b)
FPQ 51
C17H19ClFN3O3
Ethyl F 4-Methyl-piperazin-1-yl Cl 219.6-221
Pintilie et al.
(2014b)
FPQ 27
C17H20FN2O3
Ethyl F 3-Methyl-piperazin-1-yl H 177.6-180.6
Pintilie et al.
(2014a)
AcFPQ 27
C19H22FN3O4
Ethyl F 4-Acetyl-3-methyl-piperazin-1-yl H 247.5-248.9
Pintilie & Nita
(2011a)
AcFPQ29
C19H21ClFN3O4
Ethyl F 4-Acetyl-3-methyl-piperazin-1-yl Cl 262.7-264.8
Pintilie & Nita
(2011a)
FPQ29 . HCl
C17H29ClFN2O3 .HCl
Ethyl F 3-Methyl-piperazin-1-yl Cl 280-283 Pintilie & Nita(2011a)
6ClPQ 24
C18H21ClN2O3
Ethyl Cl 3-Methyl-piperidin-1-yl H 216,4-218,4
Pintilie et al.
(2009b)
6ClPQ 30
C18H20Cl2N2O3
Ethyl Cl 3-Methyl-piperidin-1-yl Cl 190.3-192.2
Pintilie & Nita
(2011b)
6ClPQ 32
C17H19ClN2O3
Ethyl Cl Piperidin-1-yl H 234.6-236.4
Pintilie & Nita
(2011b)
6ClPQ 33
C17H18Cl2N2O3
Ethyl Cl Piperidin-1-yl Cl 214.6-216.3
Pintilie & Nita
(2011b)
PQ 80
C18H21ClN2O3
Ethyl Cl 4-Methyl-piperidin-1-yl H 262.5-264.4
Pintilie & Nita
(2011b)
PQ87
C18H20Cl2N2O3
Ethyl Cl 4-Methyl-piperidin-1-yl Cl 152.3-154.9
Pintilie & Nita
(2011b)
6ClPQ 35
C17H18Cl2N2O3
Ethyl Cl Pyrrolidin-1-yl H 312.3-315.5
Pintilie & Nita
(2011b)
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Quinolones R1 R6 R7 R8 m.p. (°C) Reference
6ClPQ 36
C17H18Cl2N2O3
Ethyl Cl Pyrrolidin-1-yl Cl 172.4-176.1
Pintilie & Nita
(2011b)
6ClPQ 25
C16H17ClN2O4
Ethyl Cl Morpholin-1-yl H 267,1-269,2
Pintilie et al.
(2009b)
6ClPQ 28
C16H16Cl2N2O4
Ethyl Cl Morpholin-1-yl Cl 213.9-216.7
Pintilie & Nita
(2011b)
NClX
C16H18ClN3O3
Ethyl Cl Piperazin-1-yl H 226.8-228.5
Pintilie et al.
(2014b)
AcNClX
C18H20ClN3O4
Ethyl Cl 4-Acetyl-piperazin-1-yl H 306-310 Pintilie et al.(2014b)
Ac6ClPQ 50
C18H19Cl2N3O4
Ethyl Cl 4-Acetyl-piperazin-1-yl Cl 260.1-263.7
Pintilie et al.
(2014b)
6ClPQ 50
C16H17Cl2N3O3
Ethyl Cl Piperazin-1-yl Cl 228.2-230.4
Pintilie et al.
(2014b)
PClX
C17H20ClN3O3
Ethyl Cl 4-Methyl-piperazin-1-yl H
253.7-258.
2
Pintilie et al.
(2014b)
6ClPQ 51
C17H19Cl2N3O3
Ethyl Cl 4-Methyl-piperazin-1-yl Cl 223.4-226
Pintilie et al.
(2014b)
6ClPQ 27
C17H20ClN3O3
Ethyl Cl 3-Methyl-piperazin-1-yl H 170.5-171.4
Pintilie et al.
(2009b)
Ac6ClPQ 27
C19H22ClN3O4
Ethyl Cl 4-Acetyl-3-methyl-piperazin-1-yl H 275-276 Pintilie et al.(2014 b)
Ac6ClPQ 29
C19H21Cl2N3O4
Ethyl Cl 4-Acetyl-3-methyl-piperazin-1-yl Cl 210.3-211.7
Pintilie et al.
(2014b)
6ClPQ 29
C17H19Cl2N2O3
Ethyl Cl 3-Methyl-piperazin-1-yl Cl 278.5-282 Pintilie et al.(2014b)
Table 11. Oxo-1,4-dihydro-quinoline-3-carboxylic acids synthesized.
3.2. Synthesis pathway
The synthesis of the novel quinolones followed a Gould–Jacobs cyclization process (Scheme
1). Appropriate unsubstituted aniline (1) is reacted with diethylethoxy methylene malonate
(EMME) to produce the resultant anilinomethylenemalonate. A subsequent thermal process
induces Gould–Jacobs cyclization to afford the corresponding 4-hidroxy-quinoline-3-carbox‐
ylate ester (2). The following operation is the alkylation of the quinolone, which is usually
accomplished by reaction with a suitable alkyl halide or dialkyl sulphates to produce the
qinolone-3-carboxylate ester (3). The final manipulation is acid or basic hydrolysis to cleave
the ester generating the biologically active free carboxylic acid (4). The biologically active free
carboxylic acid (4) was also obtained from the corresponding 4-hidroxy-quinoline-3-carboxy‐
late ester (2) by alkylation with dialkyl sulphates in presence of alkali, for example, the reaction
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it can conveniently be carried out in aqueous 40% sodium hydroxide solution. The displace‐
ment of 7-chloro group with a heterocyclic yielded compounds (5). 8-Chloro-quinoline-3-
carboxylic acid (8) was synthesized from 8-unsubstituted quinoline-3-carboxylic acid (5) by
chlorination with sulfuryl chloride (when R7 = 4-methyl-piperazine). When R7 = 3-methyl-
piperazine or piperazine, it is necessary to protect the nitrogen atom from piperazine group.
After chlorination and hydrolysis, the final compound (8) is obtained (R7 = 3-methyl-pipera‐
zine, or piperazine).
7
8
for R7  =
HN N
RR= H, CH3
CH3 COCl
CH3 CO2 H
R6
Cl NH2
1 . EMME
2 .Dow term N
R6
Cl
OH
CO2 C2 H5 DES / K2 CO3
DMF N
O
C2 H5
CO2 C2 H5R6
Cl
N
O
C2 H5
CO2 HR6
Cl
1 . NaOH
2. CH3 CO2 H
1. DES / NaOH 40%
2 . HCl
R7 H
N
O
C2 H5
CO2 HR6
R7N
O
C2 H5
CO2 HR6
R7
2 3
45
SO2 Cl2
for: R7  = 
NNCH3
NCH3
N
CH3
N
NO
N
N
O
C2 H5
CO2 HR6
N
NCH3 CO
R
N
O
C2 H5
CO2 HR6
N
NCH3 CO
R
Cl 6
SO2 Cl2
hydrolysis
1
Cl
 
Figure 20. Synthesis of the new quinolones.
3.3. Antibacterial activity of the new compounds
The new compounds were evaluated for “in vitro” activity by determining minimum inhibi‐
tory concentration against bacteria E. coli, S. aureus, and P. aeruginosa, by agar dilution method
(Buiuc 1998) (NCCLS 2003) (Table 12). After analyzing chemical structure–biological activity
relationships, it was observed that the presence of chlorine in 8 position of the quinolones core
leads to increased antimicrobial activity for the compounds having piperidinyl, morpholinyl,
and pyrrolidinyl moiety in 7-position. For 7-piperazinyl quinolones, the chlorine atom from
8-position leads to decreased activity against all the tested strains.
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Quinolone
Minimum inhibitory concentration
μg/ml References
E. coli (a) S. aureus (b) P. aeruginosa (c)
FPQ 24 2.00 0.50 32.00 Pintilie et al. 2009b
FPQ 30 0.32 0.125 1.28 Pintilie & Nita 2011a
FPQ 32 1.00 8.00 8.00 Pintilie & Nita 2011a
FPQ 33 0.32 0.32 1.28 Pintilie & Nita 2011a
Q 83 3,12 1,56 6,25 Pintilie et al. 2003b
Q 85 3,12 0,39 6,25 Pintilie et al. 2003b
FPQ 35 31.25 1.953 "/>125 Pintilie & Nita 2011a
FPQ 36 15.625 0.244 15.625 Pintilie & Nita 2011a
FPQ 28 0,125 0,06 8,00 Pintilie et al. (2009b)
NF <0.08 0.32 0.32 Pintilie et al. 2014 b
FPQ 50 2.00 4.00 16.00 Pintilie et al. 2014 b
PF <0.08 1.28 1.28 Pintilie et al. 2014 b
FPQ 51 2.00 4.00 32.00 Pintilie et al. 2014 b
FPQ 27 0.125 1.00 1.00 Pintilie & Nita 2011a
FPQ 29 0.30 1.21 4.83 Pintilie & Nita 2011a
6ClPQ 24 8,00 2,00 "/>128 Pintilie et al. (2009b)
6ClPQ 30 8.00 2.56 2.56 Pintilie & Nita 2011b
6ClPQ 33 2.56 2.56 2.56 Pintilie & Nita 2011b
6ClPQ 36 2.56 2.56 2.56 Pintilie & Nita 2011b
6ClPQ 28 1.28 1.28 64 Pintilie & Nita 2011b
NClX 0.32 1.28 5.12 Pintilie et al. 2014 b
6ClPQ 50 2.00 8.00 32.00 Pintilie et al. 2014 b
PClX 0.32 1.28 5.12 Pintilie et al. 2014 b
6ClPQ 51 3.906 15.625 62.5 Pintilie et al. 2014 b
a. E. coli ATCC 8739, b. S. aureus ATCC 6538, c. P. aeruginosa ATCC 9027
Table 12. “In vitro” antibacterial activity of the new quinolones.
3.4. Antibacterial activity of the new compounds against methicillin-resistant S. aureus
Some of the new quinolones, which showed a good activity, have been tested against 30 strains
of methicillin-resistant S. aureus isolated in the Microbiology Laboratory of INBI Prof. “Dr.
Matei Bals” during 2012. The minimum inhibitory concentration (MIC) of the isolates has been
determined by agar plate Mueller Hinton (bioMerieux) dilution method using the reference
strain S. aureus ATCC 29213. The 30 strains of isolated have been also tested for susceptibility
to ciprofloxacin, levofloxacin, and imipenem by Etest method.
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Figure 21. MIC histograms of 4 quinolones against 30 strains of methicillin-resistant S. aureus.
   
 
Figure 22. MIC histograms of ciprofloxacin, levofloxacin, imipenem against 30 strains of methicillin-resistant S. aureus,
determined by Etest method.
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Base on the “in vitro” studies, the quinolone FPQ-30 appears to be a promising compound; all
strains isolates were inhibited at a concentration of 8 μg/ml (Figure 21).
4. Conclusion
In conclusion, we have synthesized new quinolone compounds and we have investigated their
activity against multidrug-resistant gram positive microorganisms. Of the four compounds,
FPQ-30 (Figure 23, 24) showed the best activity; all strains isolates were inhibited at a concen‐
tration of 8 μg/ml. The results of the present study indicate the quinolone FPQ-30 appears to
be a promising compound.
Its structure has been determined and confirmed by the following physicochemical methods:
elemental analysis, IR spectral analysis, H-NMR, C-NMR, UV (Figure 25) and thin layer
chromatography.
N
O
COOHF
N
Cl CH2CH3
CH3 1 2
3456
7 8
9
10 11
1213
14 15 16
1a
4a13'
1H-NMR(dmso-d6, δ ppm, J Hz, T = 333K): 8.88(s, 1H, H-2); 7.93(d, 1H, H-5, 3J(F-H5) = 13.4 Hz); 4.81(q, 2H, H-10, 7.1);
3.28(m, 2H, H-16, H-12); 3.11(dd, 1H, H-12, 10.7, 12.1); 2.81(td, 1H, H-16, 12.1, 2.9); 1.58 ÷ 1.86(m, H, H-13, 2H-14,
1H-15); 1.39(t, 3H, H-11, 7.1); 1.13(qd, 1H, H-15, 10.8, 4.1); 0.88(d, 3H, H-13, 6.4).
13C-NMR(dmso-d6, δ ppm): 175.89(d, C-4, 4J(F-C4) = 2.8 Hz); 167.30(C-9); 155.83(d, C-6, J(F-C6) = 251.1 Hz); 152.45(C-2);
144.37(d, C-7, 2J(F-C7) = 14.3 Hz); 136.46(C-1a); 122.95(d, C-4a, 3J(F-C4a) = 7.1 Hz); 118.93(C-8); 110.79(d, C-5, 2J(F-C5) =
23.4 Hz); 107.67(C-3); 58.70 (d, C-12, 4J(F-C12) = 4.6 Hz); 53.06(C-10); 51.57(d, C-16, 4J(F-C16) = 4.6 Hz); 32.05(C-15);
31.17(C-13); 25.39(C-14); 18.82(C-13);15.73(C-11).
FT-IR(solid in ATR, ν/cm): 3059m; 2947w; 2925m; 2867w; 2845m; 1719vs; 1616s; 1558s; 1531m; 1489m; 1437vs; 1381m;
1319m; 1294m; 1250m; 1229m; 1208m; 1189m; 1125w; 1101m; 1081m; 1040m; 996w; 968w; 926m; 887m; 857w; 838w;
8.05m; 741w.
Figure 23. Ethyl-6-fluoro-7-(4-methyl-piperidinyl)-8-chloro- Optimized molecular structure of FPQ 30
Figure 24. dihydro-4-oxo-quinoline-3-carboxylic acid (FPQ 30) with Spartan 14 Software
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Figure 25. UV absorption spectrum of FPQ-24 and FPQ-30
UV absorption spectra study was carried out using solutions with oncentration of 10 mg/ml
in chloroform. Interpretation of the UV absorption spectrum has been made in comparison
with that of the quinolone compound: 1-ethyl-6-fluoro-7-(3-methyl-piperidin-1-yl)-1,4-
dihydro-4-oxo-quinoline-3-carboxylic acid (FPQ 24), namely:
• The presence of the quinolone nucleus determines in chloroform the appearance of elec‐
tronic transitions in the field of 260–310 nm and 320–350 nm.
• The introduction of chlorine atom in 8 position produces a batocroma displacement of the
entire spectrum.
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